This double-blind, randomized, placebo-controlled pilot study was designed to evaluate effects of consumption of an antioxidant-rich, yeast culture-based high-metabolite immunogen EpiCor®. Twenty-five healthy participants consumed 0.5 gram EpiCor® or placebo daily for 5 weeks. The hematocrit increased significantly in the EpiCor® group (p < 0.04). A mild increase in saliva sIgA upon EpiCor® consumption (p=0.16) prompted a subsequent 8-week open-label study involving 22 people showing significant increase in sIgA (p < 0.05). EpiCor® consumption led to a mild increase in serum IL-10 (p < 0.2); no other differences in Th1/Th2 cytokines were observed. Minor health complaints decreased in the EpiCor® group compared to the placebo group (p < 0.02). Seasonal allergies increased in the placebo group, but were not observed in the EpiCor® group; this was reflected by increased serum IgE in the placebo group compared to the EpiCor® group (p < 0.13). We conclude that consumption of EpiCor® supported the health of red blood cells and mucosal immune protection.